Table 1

Summary of dataset variables

MeasureDetailsSource
Intake: baseline data
 Demographic informationDate of birth
Race
Weight and height
Patient
 Family history of cancerPatient reportedPatient
 Modified Charlson comorbidity index questionnairePatient reportedPatient
Data updated annually for 5 years
 Medication questionnaireCurrent use of prescribed and over-the-counter medications, vitamins, supplements, etc.
Smoking history
Fasting status
Patient and clinical data abstraction
 Patient-reported health statusIPSS
EPIC-26 SF
EQ-5D-5L
Patient
 Biospecimen informationCollection and processing informationAPCaRI team
Diagnosis: clinical data sources are reviewed every 6 months and new data are entered in the APCaRI Registry as applicable
 PSAThree most recent values before histological diagnosisClinical data abstraction
 PathologyComplete pathology report from biopsy, TURP and/or radical retropubic prostatectomy
Gleason grade and score
Disease involvement and location
Clinical and pathologic staging
Margin status and invasion
Clinical data abstraction
 ImagingBone scan
MRI
CT scan
Other
Clinical data abstraction
Treatment: clinical data sources are reviewed every 6 months and new data are entered in the APCaRI Registry as applicable
 Active surveillanceStart and end date
Failure
Reason for failure
Treatment option
Clinical data abstraction
 Radical prostatectomyDate
Type of procedure
Nerve sparing
Surgical time
Blood loss
Complications
Clinical data abstraction
 External beam radiation therapyDate
Start and end date
Treatment intent
Goals of care
Type
Technique
RT volume
Dose
Fractions
Radionuclide
Complications
Clinical data abstraction
 BrachytherapyDateClinical data abstraction
 CryotherapyDate
Type (primary/salvage)
Clinical data abstraction
 Androgen deprivation therapyAgent
Start and end date
Dosage
Intention of treatment
Clinical data abstraction
 Chemotherapy*Agent
Line of treatment
Start and end date
Dosage
Number of cycles
Treatment intent
Clinical data abstraction
 Clinical trialsAgent
Line of treatment
Start and end date
Dosage
Number of cycles
Treatment intent
Clinical data abstraction
Survival and disease control: clinical data sources are reviewed every 6 months and new data are entered in the APCaRI Registry as applicable
 Disease progressionType of progression
PSA values and date
Date
Castrate-resistance status
Clinical data abstraction
 Metastasis-free survivalSite
Date
Skeletal event
Clinical data abstraction
 Cause-specific survivalCause of deathClinical/administration
 Overall survivalDate of deathClinical/administration
  • *Chemotherapy includes anti-androgens, hormones, corticosteroids and radioisotopes

  • APCaRI, Alberta Prostate Cancer Research Initiative; EPIC-26 SF, Expanded Prostate Index Composite, 26 Item, Short Form; EQ-5D-5L, five-level EuroQol Five-Dimension Questionnaire; IPSS, International Prostate Symptom Score; PSA, prostate specific antigen; TURP, transurethral resection of prostate.